ARA-290
Activates the innate repair receptor (IRR) to promote tissue repair without immunosuppressive effects of EPO.
Medically reviewed by Dr. Jonathan Snipes, MD. Last reviewed May 6, 2026.What It Is
ARA-290 is an 11-amino acid peptide that activates the innate repair receptor. It was developed from erythropoietin (EPO) research but without EPO's blood-thickening effects.
How It Works
It activates repair pathways in damaged tissues, reduces inflammation, and has been shown to promote nerve repair and reduce neuropathic pain.
Who It's For
Those with neuropathy, nerve damage, or chronic pain conditions. Also used for general tissue repair and inflammation reduction.
Who Should Avoid It
Generally well-tolerated. Discuss with provider if on blood-related medications.
Protocol & Pricing
OBP Pharmacy Price
$80/30mg
You pay pharmacy price. No markup.
Starting Dose
20 units (1.2mg)
Form
Injectable vial (5mL, 6mg/mL, 30mg total)
Dosing Protocol
20 units subcutaneous injection daily. 20 units = 0.2mL × 6mg/mL = 1.2mg per injection. 4–12 weeks duration, may be cycled or extended.
Beyond Use Date
90 Days from compounding (USP <797>)
Use within this window from the date your vial is compounded. BUD is set per USP <797> sterile compounding standards and printed on every label.
Stacking Guide
Stacks Well With
Related Peptides
Common questions about ARA-290
- What is ARA-290?
- ARA-290 (also known as cibinetide) is an 11-amino acid peptide derived from erythropoietin (EPO) but with the EPO segment removed that triggers red blood cell production. The remaining sequence binds the innate-repair receptor on tissues, promoting nerve repair and reducing inflammation without the polycythemia risks of EPO. ARA-290 has been studied for diabetic neuropathy, sarcoidosis, and chronic neuropathic pain.
- Does ARA-290 work for nerve pain and inflammation?
- Phase II clinical trials showed ARA-290 reduced neuropathic pain scores in patients with sarcoidosis-associated small fiber neuropathy and improved corneal nerve fiber density in diabetic neuropathy. The peptide has not progressed to FDA approval but compounding-clinic use draws on the trial-evidence base. Effects are gradual; most protocols run at least 4 weeks before assessment.
- How is ARA-290 dosed?
- Common subcutaneous protocols deliver 1 to 4 mg per day for 4 to 8 weeks at a time. Optimal Balance Pharmacy compounds ARA-290 against PeptideRx prescriptions; your provider sets the dose based on the specific neuropathic indication and your medical history.
- Where do I inject ARA-290?
- Subcutaneously into the abdomen, upper outer thigh, or back of the upper arm using a 31-gauge, 5/16-inch (8 mm) needle on a U-100 insulin syringe. Sterile syringes are included with every PeptideRx shipment. Rotate sites between injections.
- How is ARA-290 supplied?
- Compounded by Optimal Balance Pharmacy under a 503A patient-specific prescription. Ships pre-reconstituted and ready to inject in cold-chain packaging. Every batch is tested by Eagle Analytical Services; the Certificate of Analysis is published on this product page.